SRR12202463
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.470
- MYC_TARGETS_V2+0.410
- MYC_TARGETS_V1+0.390
- UNFOLDED_PROTEIN_RESPONSE+0.320
- PROTEIN_SECRETION+0.300
- ANGIOGENESIS+0.270
- G2M_CHECKPOINT+0.260
- PI3K_AKT_MTOR_SIGNALING+0.260
- MITOTIC_SPINDLE+0.250
- NOTCH_SIGNALING+0.220
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.420
- INTERFERON_GAMMA_RESPONSE-0.320
- BILE_ACID_METABOLISM-0.270
- CHOLESTEROL_HOMEOSTASIS-0.240
- HYPOXIA-0.220
- ALLOGRAFT_REJECTION-0.210
- IL6_JAK_STAT3_SIGNALING-0.200
- FATTY_ACID_METABOLISM-0.140
- P53_PATHWAY-0.140
- APICAL_SURFACE-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12202472 | — | — | 0.791 |
| 2 | TCGA-75-7027-01A-11R-1949-07 | — | cohortA4 | 0.752 |
| 3 | SAMN03290906 | — | — | 0.744 |
| 4 | MNG646 | — | — | 0.727 |
| 5 | SRR2932813 | — | — | 0.712 |
| 6 | d9eacc36-0ae3-41bd-aef6-503f91cb25aa | — | — | 0.709 |
| 7 | MNG409 | — | — | 0.708 |
| 8 | s0122203 | — | — | 0.703 |
| 9 | MNG732 | — | — | 0.696 |
| 10 | SRR934938 | — | — | 0.694 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.470 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.410 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.390 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.270 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.260 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.260 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.250 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.220 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| COAGULATION | 0.170 | Binimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.170 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.160 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.130 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.130 | Cobimetinib | — uncovered |
| E2F_TARGETS | 0.120 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.120 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |